secwatch.observer — SEC 8-K summary
======================================

Issuer:     Envoy Medical, Inc. (COCH)
CIK:        0001840877
Form:       8-K
Filed at:   2026-04-21T23:59:59+00:00
Accession:  0001213900-26-046197
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Envoy Medical appoints Charles McKhann as Class I director and to Compensation Committee
--------------------------------------------------------------------------------

- Board size increased from 6 to 7 members; McKhann appointed to Compensation Committee.
- Awarded stock options for 100,000 shares at $0.72/share, vesting monthly over 36 months.
- McKhann previously CEO of Silk Road Medical (acquired by Boston Scientific) and Apollo Endosurgery (also acquired by Boston Scientific).
- McKhann is independent under Nasdaq listing standards and SEC rules.
- Appointment effective April 15, 2026; term expires at 2027 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840877/000121390026046197/0001213900-26-046197-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840877/000121390026046197/ea028718601-8k_envoymedical.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-046197

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer